{"id":2749,"date":"2020-06-01T12:00:00","date_gmt":"2020-06-01T10:00:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2020\/intravitreale-therapie-der-neovaskulaeren-altersabhaengigen-makuladegeneration-mit-vegf-inhibitoren"},"modified":"2020-06-01T12:00:00","modified_gmt":"2020-06-01T10:00:00","slug":"intravitreale-therapie-der-neovaskulaeren-altersabhaengigen-makuladegeneration-mit-vegf-inhibitoren","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2020\/intravitreale-therapie-der-neovaskulaeren-altersabhaengigen-makuladegeneration-mit-vegf-inhibitoren","title":{"rendered":"Intravitreale Therapie der neovaskul\u00e4ren altersabh\u00e4ngigen Makuladegeneration mit VEGF-Inhibitoren"},"content":{"rendered":"<p>Zusammenfassung: Die altersabh\u00e4ngige Makuladegeneration (AMD) ist die h\u00e4ufigste Ursache f\u00fcr Erblindung der \u00e4lteren Bev\u00f6lkerung in Industriel\u00e4ndern. Die neovaskul\u00e4re oder \u201efeuchte\u201c Sp\u00e4tform der Erkrankung f\u00fchrt unbehandelt zu einem irreversiblen Verlust des zentralen Sehens. Seit dem Jahr 2004 steht mit mehreren Vascular Endothelial Growth Factor (VEGF)-Inhibitoren eine wirksame und sichere Therapie zur Verf\u00fcgung. In Deutschland zugelassen und [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zusammenfassung: Die altersabh\u00e4ngige Makuladegeneration (AMD) ist die h\u00e4ufigste Ursache f\u00fcr Erblindung der \u00e4lteren Bev\u00f6lkerung in Industriel\u00e4ndern. Die neovaskul\u00e4re oder \u201efeuchte\u201c Sp\u00e4tform der Erkrankung f\u00fchrt unbehandelt zu einem irreversiblen Verlust des zentralen Sehens. Seit dem Jahr 2004 steht mit mehreren Vascular Endothelial Growth Factor (VEGF)-Inhibitoren eine wirksame und sichere Therapie zur Verf\u00fcgung. In Deutschland zugelassen und [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[3104,1520,5382,5379,4299,2156,5384,5380,5381,5383,5385,5387,5386,2988,4300,2968,5375,5376,3979,3981,4799,5377,5378],"class_list":["post-2749","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-abc-studie","tag-aflibercept","tag-altersabhaengige-makuladegeneration","tag-amd","tag-anchor-studie","tag-bevacizumab","tag-blindheit","tag-brolucizumab","tag-catt-studie","tag-erblindung","tag-frb-studie","tag-harrier-studie","tag-hawk-studie","tag-makuladegeneration","tag-marina-studie","tag-ranibizumab","tag-sehkraft","tag-sehschaerfe","tag-vascular-endothelial-growth-factor","tag-vegf","tag-vegf-inhibitoren","tag-view-studie","tag-wave-studie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2749","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2749"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2749\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2749"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2749"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2749"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}